Therapeutic Asset Ratings

1,027 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Immunoglobulin G1 [de-448-lysine], anti-(human epidermal growth factor receptor) (human-mouse monoclonal C225 ?1-chain) fusion protein with peptide linker (GGGGS)2 fusion protein with immunoglobulin anti-(human epidermal growth factor receptor HER3) (human clone HER3.H3 single-chain variable fragment VH-(GGGGS)3-VL), complex with human-mouse monoclonal C225 ?-chain, dimer, 214??,214???,222,222?,228,228?,231,231?-octakis(thioether) with (2S)-N-(carboxymethyl)-2-(3-mercapto-2,5-dioxo-1-pyrrolidinyl)-?-alanylglycylglycyl-L-phenylalanyl-N-[[(1S)-2-[[(1S,9S)-9-ethyl-5-fluoro-2,3,9,10,13,15-hexahydro-9-hydroxy-4-methyl-10,13-dioxo-1H,12H-benzo[de]pyrano[3?,4?:6,7]indolizino[1,2-b]quinolin-1-yl]amino]-1-methyl-2-oxoethoxy]methyl]glycinamide Small Cell Lung Carcinoma	Sichuan Baili Pharmaceutical Co., Ltd.	P3	B (60)
Immunoglobulin G1 [de-448-lysine], anti-(human epidermal growth factor receptor) (human-mouse monoclonal C225 ?1-chain) fusion protein with peptide linker (GGGGS)2 fusion protein with immunoglobulin anti-(human epidermal growth factor receptor HER3) (human clone HER3.H3 single-chain variable fragment VH-(GGGGS)3-VL), complex with human-mouse monoclonal C225 ?-chain, dimer, 214??,214???,222,222?,228,228?,231,231?-octakis(thioether) with (2S)-N-(carboxymethyl)-2-(3-mercapto-2,5-dioxo-1-pyrrolidinyl)-?-alanylglycylglycyl-L-phenylalanyl-N-[[(1S)-2-[[(1S,9S)-9-ethyl-5-fluoro-2,3,9,10,13,15-hexahydro-9-hydroxy-4-methyl-10,13-dioxo-1H,12H-benzo[de]pyrano[3?,4?:6,7]indolizino[1,2-b]quinolin-1-yl]amino]-1-methyl-2-oxoethoxy]methyl]glycinamide Triple-Negative Breast Carcinoma	Sichuan Baili Pharmaceutical Co., Ltd.	P3	B (60)
Inotuzumab Ozogamicin Central Nervous System Leukemia	Children's Oncology Group	P3	B (60)
Inotuzumab Ozogamicin Testicular Leukemia	Children's Oncology Group	P3	B (60)
Maridebart Cafraglutide Atherosclerotic Cardiovascular Disease	Amgen	P3	B (60)
Maridebart Cafraglutide Heart Failure	Amgen	P3	B (60)
Maridebart Cafraglutide Diastolic Heart Failure	Amgen	P3	B (60)
Maridebart Cafraglutide Obstructive Sleep Apnea	Amgen	P3	B (60)
Maridebart Cafraglutide Type 2 Diabetes Mellitus (T2DM), Obesity, Overweight	Amgen	P3	B (60)
Mirvetuximab Soravtansine Fallopian Tube Neoplasm	Eli Lilly and Company	P3	B (60)
Mirvetuximab Soravtansine Peritoneal Neoplasm	Eli Lilly and Company	P3	B (60)
Puxitatug Samrotecan Cancer	AstraZeneca	P3	B (60)
rc48-adc Cancer	LaNova Medicines Limited	P3	B (60)
rc48-adc First-line Treatment	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	P3	B (60)
rc48-adc Hormone Receptor-Positive Breast Cancer	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	P3	B (60)
rc48-adc Microsatellite Instability High	Sun Yat-sen University	P3	B (60)
Sacituzumab Tirumotecan Adjuvant Drug Therapy	Fudan University	P3	B (60)
Sacituzumab Tirumotecan Triple-Negative Breast Carcinoma	Yale University	P3	B (60)
Trastuzumab Deruxtecan Basal-Like Breast Carcinoma	Danish Breast Cancer Cooperative Group	P3	B (60)
Trastuzumab Deruxtecan Female Breast Carcinoma	Sun Yat-sen University	P3	B (60)
Trastuzumab Deruxtecan Luminal B Breast Carcinoma	Danish Breast Cancer Cooperative Group	P3	B (60)
Trastuzumab Emtansine Residual Invasive Breast Cancer	Daiichi Sankyo	P3	B (60)
Trastuzumab Emtansine Synchronous Bilateral Breast Carcinoma	Alliance for Clinical Trials in Oncology	P3	B (60)
Brentuximab Vedotin Mature T-Cell And NK-Cell Non-Hodgkin Lymphoma	The First Affiliated Hospital of Soochow University	P2	B (60)
Brentuximab Vedotin Follicular Lymphoma	University of California, Davis	P2	B (60)

Showing 126 to 150 of 1,027 assets

PreviousPage 6 of 42Next